JSSH(SZ:000518)2019-04-15 16:00Financial Performance - In 2018, the company's operating revenue was CNY 395,514,079.67, representing a 14.29% increase compared to CNY 346,054,646.61 in 2017[17]. - The net profit attributable to shareholders was a loss of CNY 29,439,589.94, a decrease of 503.92% from a profit of CNY 7,288,394.73 in 2017[17]. - The net cash flow from operating activities was CNY 22,566,810.71, a significant improvement of 309.23% compared to a negative cash flow of CNY 10,785,813.91 in 2017[17]. - The total revenue of the company for 2018 was CNY 395,034,995.03, representing a year-on-year increase of 15.61%[41]. - The net loss for the period was CNY 29,716,740.02, compared to a net profit of CNY 10,650,335.19 in the previous period[183]. - The company reported a net profit of -2,115,792.0 for the period, indicating a significant loss[66]. - The company reported a comprehensive income loss of -29,439,000.00 for the current period[199]. Assets and Liabilities - The total assets at the end of 2018 were CNY 925,876,050.58, a decrease of 0.62% from CNY 931,628,406.78 at the end of 2017[17]. - The company's total assets reached CNY 733,041,880.49, up from CNY 717,167,468.04 in the previous period[180]. - Total liabilities increased from CNY 256,083,448.72 to CNY 283,074,232.54, an increase of approximately 10.5%[177]. - The company's total equity decreased from CNY 675,544,958.06 to CNY 642,801,818.04, a decline of about 4.9%[177]. - Cash and cash equivalents decreased from CNY 40,728,343.14 to CNY 39,429,625.90, a decline of about 3.2%[175]. - Short-term borrowings increased from CNY 50,000,000.00 to CNY 70,000,000.00, an increase of 40.0%[177]. Revenue Segmentation - The pharmaceutical segment generated CNY 334.19 million, accounting for 84.49% of total revenue, but saw a decline of 9.02% compared to the previous year[38]. - The ecological forestry segment reported a revenue increase of 187.26% during the reporting period[35]. - The company’s main products include EPO and interleukin, with EPO sales increasing by 3.41% to CNY 139.92 million, while interleukin sales decreased by 3.87% to CNY 155.22 million[38]. - Domestic sales accounted for 98.53% of total revenue, amounting to CNY 389,711,999.03, while international sales were only CNY 3,322,996.00[41]. Research and Development - R&D expenses rose by 46.60% to ¥12,583,889.89, representing 3.18% of operating revenue[52]. - The number of R&D personnel increased by 20.00% to 6, representing 2.59% of total employees[52]. - New product development initiatives are underway, with an investment of 50 million RMB allocated for R&D in 2019, focusing on innovative biopharmaceuticals[131]. Corporate Governance and Compliance - The company emphasizes the importance of timely and accurate information disclosure to protect investor rights[79]. - The company has appointed Zhongzheng Zhonghuan Accounting Firm as its auditor for the 2018 fiscal year, with an audit fee of 1.28 million yuan[84]. - The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[110]. - The company has established a governance structure to ensure compliance with relevant laws[105]. Future Outlook and Strategy - The company’s future outlook remains optimistic due to the anticipated growth in the pharmaceutical industry, driven by increasing healthcare spending and an aging population[27]. - The company plans to enhance its internal control and risk management to improve operational efficiency in 2019[69]. - The company plans to expand its market presence, targeting an increase in market share by 10% in the next fiscal year through strategic partnerships[131]. - A potential acquisition is being considered to enhance product offerings, with discussions ongoing for a merger with a complementary biotech firm[131]. Employee and Management Structure - The total number of employees in the company is 314, with 307 in major subsidiaries and 7 in the parent company[136]. - The educational background of employees shows that 73 hold a bachelor's degree or above, 84 have a college diploma, and 157 have a vocational or lower education level[137]. - The management team emphasized the importance of cost control, aiming to reduce operational expenses by 5% in 2019[131]. - The company maintains a stable management structure with no significant changes in executive positions during the reporting period[125]. Financial Management and Investments - The company reported a total of 2,300 million CNY in entrusted financial management during the reporting period, with no overdue amounts[103]. - The company did not engage in any securities or derivative investments during the reporting period[61][62]. - The company has no outstanding bonds that are due or unable to be fully repaid as of the annual report approval date[161].